Lansoprazol Quimedical

Lansoprazole, the active ingredient in Lansoprazol Quimedical, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is used to manage conditions such as gastro‑esophageal reflux disease, peptic ulcer disease, erosive esophagitis, and as part of Helicobacter pylori eradication regimens.

GNH USA supplies Lansoprazol Quimedical as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor that acts on gastric acid secretion pathways, providing therapeutic benefit in several acid‑related disorders. - Gastro‑esophageal reflux disease (GERD): reduces acid exposure and relieves heartburn and regurgitation symptoms. - Peptic ulcer disease: promotes ulcer healing by maintaining a higher gastric pH. - Erosive esophagitis: facilitates mucosal repair and symptom control. - Helicobacter pylori eradication regimens: enhances the effectiveness of antibiotic combinations by suppressing gastric acidity.

Adverse reactions may occur with lansoprazole therapy. Most are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea: occasional, may improve with food. - Abdominal pain: mild discomfort. - Flatulence: increased intestinal gas. - Constipation: occasional bowel habit change.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): requires immediate medical attention. - Clostridioides difficile infection: possible with prolonged use. - Low serum magnesium (hypomagnesemia): may cause muscle cramps or arrhythmia. - Osteoporotic fractures: increased risk with long‑term therapy. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: rare but serious skin reactions. - Elevated liver enzymes: monitor hepatic function if symptoms arise.

Before initiating lansoprazole, consider the following safety measures. - Assess renal function: adjust use in severe impairment. - Monitor for infections: prolonged acid suppression may increase risk of gastrointestinal infections. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Use caution in elderly patients: higher incidence of bone fractures. - Store at ambient temperature: keep in the original pack, protect from moisture.

Lansoprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Ketoconazole: reduced absorption and efficacy. - Atazanavir: decreased plasma concentrations. - Clopidogrel: diminished antiplatelet activation.

Moderate Interactions (Monitor Closely): - Digoxin: potential increase in serum levels. - Methotrexate: heightened toxicity risk. - Phenytoin: possible reduction in anticonvulsant effect.